AIM: To report the long-term results of high-dose-rate (HDR) brachytherapy (BT) boost for breast cancer patients treated with conservative surgery and radiotherapy. MATERIALS AND METHODS: Between 1995 and 2007, 100 early-stage breast cancer patients received an HDR BT boost after conservative surgery and whole breast irradiation. Ten patients (10%) received a single-fraction HDR boost of 8-10.35 Gy using rigid needles, while 90 (90%) were treated with a fractionated multi-catheter HDR BT boost. The latter consisted of 3 × 4 Gy (n = 19), 3 × 4.75 Gy (n = 70), and 2 × 6.4 Gy (n = 1). Breast cancer related events, cosmetic results and side effects were assessed. RESULTS: At a median follow-up time of 94 months (range: 8-152) only 7 (7%) ipsilateral breast failures were observed for a 5- and 8-year actuarial rate of 4.5 and 7.0%, respectively. The 8-year disease-free, cancer-specific, and overall survival was 76.1, 82.8, and 80.4%, respectively. Cosmetic outcome was rated excellent in 17%, good in 39%, fair in 33%, and poor in 11%. Data on late radiation side effects were available for 91 patients (91%). Grade 3 fibrosis and grade 3 telangiectasia occurred in 6 (6.6%) and 2 (2.2%) patients, respectively. In univariate analysis only positive margin status had a significant negative effect on local control. CONCLUSIONS: HDR BT boost using multi-catheter implants produce excellent long-term local tumour control with acceptable cosmetic outcome and low rate of grade 3 late radiation side effects.
AIM: To report the long-term results of high-dose-rate (HDR) brachytherapy (BT) boost for breast cancerpatients treated with conservative surgery and radiotherapy. MATERIALS AND METHODS: Between 1995 and 2007, 100 early-stage breast cancerpatients received an HDR BT boost after conservative surgery and whole breast irradiation. Ten patients (10%) received a single-fraction HDR boost of 8-10.35 Gy using rigid needles, while 90 (90%) were treated with a fractionated multi-catheter HDR BT boost. The latter consisted of 3 × 4 Gy (n = 19), 3 × 4.75 Gy (n = 70), and 2 × 6.4 Gy (n = 1). Breast cancer related events, cosmetic results and side effects were assessed. RESULTS: At a median follow-up time of 94 months (range: 8-152) only 7 (7%) ipsilateral breast failures were observed for a 5- and 8-year actuarial rate of 4.5 and 7.0%, respectively. The 8-year disease-free, cancer-specific, and overall survival was 76.1, 82.8, and 80.4%, respectively. Cosmetic outcome was rated excellent in 17%, good in 39%, fair in 33%, and poor in 11%. Data on late radiation side effects were available for 91 patients (91%). Grade 3 fibrosis and grade 3 telangiectasia occurred in 6 (6.6%) and 2 (2.2%) patients, respectively. In univariate analysis only positive margin status had a significant negative effect on local control. CONCLUSIONS: HDR BT boost using multi-catheter implants produce excellent long-term local tumour control with acceptable cosmetic outcome and low rate of grade 3 late radiation side effects.
Authors: C Hennequin; C Durdux; M Espié; S Balla-Mekias; M Housset; M Marty; G Chotin; C Maylin Journal: Int J Radiat Oncol Biol Phys Date: 1999-08-01 Impact factor: 7.038
Authors: M A Manning; D W Arthur; R K Schmidt-Ullrich; M R Arnfield; C Amir; R D Zwicker Journal: Int J Radiat Oncol Biol Phys Date: 2000-12-01 Impact factor: 7.038
Authors: Philip Poortmans; Harry Bartelink; Jean-Claude Horiot; Henk Struikmans; Walter Van den Bogaert; Alain Fourquet; Jos Jager; Willem Hoogenraad; Patrick Rodrigus; Carla Wárlám-Rodenhuis; Laurence Collette; Marianne Pierart Journal: Radiother Oncol Date: 2004-07 Impact factor: 6.280
Authors: Jose Luis Guinot; Susana Roldan; María Maroñas; Isabel Tortajada; Maria Carrascosa; Maria Luisa Chust; Marian Estornell; Jose Luis Mengual; Leoncio Arribas Journal: Int J Radiat Oncol Biol Phys Date: 2007-04-09 Impact factor: 7.038
Authors: Alexandra Resch; Richard Pötter; Erik Van Limbergen; Eva Biber; Tanja Klein; Claudia Fellner; Leonore Handl-Zeller; Gudrun Langbauer; Helmut Schürer-Waldheim; Alfred Staffen; Raimund Jakesz; Ernst Kubista; Stephan Lehr; Wolfgang Seitz Journal: Radiother Oncol Date: 2002-04 Impact factor: 6.280
Authors: Manuel Algara; Meritxell Arenas; Dolores De Las Peñas Eloisa Bayo; Julia Muñoz; José Antonio Carceller; Juan Salinas; Ferran Moreno; Francisco Martínez; Ezequiel González; Angel Montero Journal: Rep Pract Oncol Radiother Date: 2012-04-17